EPISODE #91 Investing in Cannabis Science with Alex Ouimet-Storrs (President) and Bruce Linton (Cha

On this week’s show we’re joined by Alex Ouimet-Storrs and Bruce Linton of Óskare Capital –  European VC fund focusing on cannabinoid technology, science, and infrastructure investments. 

Join us as we explore the role of a VC fund within the cannabis industry, how they operate, and why Europe is currently the most exciting investment space worldwide. 

→ View full show notes and summary here: https://www.cannabis-conversation.com/blogs/episode 91

About Bruce

As non-executive Chairman of Óskare Capital, Canadian businessman Bruce Linton provides strategic leadership and serves as head of the investment committee. Linton is a recognized leader, visionary and entrepreneur in the cannabinoid industry. In 2013 Linton co-founded Tweed, which became Canopy Growth and was the first cannabis producer to IPO on the Nasdaq in 2018 (CGC – market cap of $7 billion).

Bruce created the world’s largest diversified and integrated cannabinoid, hemp and cannabinoid derivatives company. By working closely with external Advisors, our network of investors, and with portfolio companies of Óskare Capital, Bruce shares his industry knowledge, network and expertise.

About Alex

Alex Ouimet-Storrs is an experienced venture capital investor in Europe with a focus in Deeptech technologies and has a track record of 2.5X and 14.6% IRR, who has invested across the entire life cycle of a company (from Seed to Exit).

He began his career at Air Liquide in Paris where he spent 5 years working notably as an Industrial Risk Specialist and Energy Trading for Europe. Following Air Liquide, Alex joined Truffle Capital in 2011 as an Investment Director for the Energy branch of investing which consisted of investing in renewable power generation, energy services companies, materials, internet of things, agriculture and notably next generation chemistry. He was promoted to partner in 2014 and managed a portfolio of 11 companies, has piloted severalexits including Actility, Dymeo, ACERDE and Dietswell.

Alex joined Solvay Ventures (the corporate venture arm of the Solvay Group) as the Managing Director for the EMEA zone in 2018. He performed two investments in Invizius (Scotland) and Kumovis (Germany) that are developing medical devices. Alex also has experience setting up partnerships between the Solvay group and startups.

Alex is the co-founder of Oskare Capital, a 150 MEUR AIFM and ESG compatible fund based in Dublin that will focus on the fast-growing EU medical and pharmaceutical cannabis market. The fund has a strong team of seasoned VCs, medical doctors and researchers, pharma executives and cannabis entrepreneurs.

Alex holds a Master’s degree in Chemical Engineering from McGill University (Canada). He co-founded two startups in Canada, one of which won the Quebecois Entrepreneurship Prize in 2005.

We really are sitting on a bit of a goldmine here [in Europe] in terms of potential investment targets as well as some really groundbreaking research on the endocannabinoid system 11:40

Posted in Investors